Skip to main content

Table 1 Patient characteristics of the clinical trials reviewed

From: Thoracic perfusion of matrine as an adjuvant treatment improves the control of the malignant pleural effusions

Study Number of patients M/F Age Sources of tumor (N) Volume of MPE (N) Quality of life Pleural perfusion (N) Group 1/2 (N) End point
Yunfang et al. [15] 168 NA 38–85 Lung/pleura (102) NA KPS P + M versus P 84/84 RR, DCR, SI, AEs
Breast (32)      
Digestive tract (34)      
Sijie et al. [13] 153 68/85 32–84 Lung/pleura (117) Large (57) KPS IL-11 + P + M versus IL-11 + P 75/78 RR, DCR, SI, AEs
Breast (26) Moderate (82)     
Lymphoma (10) Small (14)     
Zenmin et al. [9] 110 NA 35–83 Lung/pleura (61) NA KPS P + M versus P 56/54 RR, DCR, SI, AEs
Breast (32)      
Digestive tract (17)      
Daiju and Xiaodong [19] 150 96/54 45-75 Lung/pleura (150) NA KPS IL-2 + M versus IL-2 75/75 RR, DCR, SI, AEs
    а-IFN + M versus a-IFN   
Zhiwen et al. [12] 90 47/43 40–77 Lung (90) NA KPS CP + M versus CP 45/45 RR, DCR, SI, AEs
Liangfa et al. [11] 98 56/42 48–73 Lung/pleura (58) Large (57) KPS P + M versus P 50/48 RR, DCR, SI, AEs
Breast (24) Moderate (23)     
Digestive tract (6) Small (18)     
Lymphoma (7)      
Others (3)      
Xiaowei et al. [10] 120 67/53 49–76 Lung/pleura (49) NA KPS MMC + M versus MMC 60/60 RR, DCR, SI, AEs
Breast (19)      
Digestive tract (32)      
Lymphoma (8)      
Others (12)      
Guoan [18] 86 54/32 65-81 Lung(86) NA KPS BLM + M versus BLM 44/42 RR, DCR, SI, AEs
Li [8] 80 46/34 20–82 Lung/pleura (29) Large (48) KPS P + M versus P 40/40 RR, DCR, SI, AEs
Breast (14) Moderate (32)     
Digestive tract (21)      
Lymphoma (7)      
Others (2)      
Ziqiang [14] 90 57/33 31–75 Lung/pleura (43) NA KPS IL-2 + M versus IL-2 + P 45/45 RR, DCR, SI, AEs
Breast (20)      
Digestive tract (18)      
Others (9)      
Yushun and Jie [16] 93 63/30 NA Lung/pleura (93) NA KPS P + M versus P 47/46 RR, DCR, SI, AEs
Zhenfeng et al. [17] 82 50/36 60–82 Lung (82) NA KPS HCPT + M versus HCPT 42/40 RR, DCR, SI, AEs
  1. Abbreviations: M/F male/ female, MPE malignant pleural effusion, Group 1 matrine combined with other therapy, Group 2 other therapy alone, KPS Karnofsky physical status score, NA not available, P cisplatin, M murine, RR response rate, DCR disease control rate, SI symptom improvement, AEs adverse effects, IL-11 interleukin-11, IL-2 interleukin-2, а-IFN а-interferon, CP Corynebacterium parvum, MMC mitomycin C, BLM bleomycin, HCPT hydroxycamptothecin